Research-Grade Metoprolol Formulation
Topme-XL 50 mg is a metoprolol tartrate extended-release formulation manufactured by Johnlee Pharmaceuticals for laboratory research applications. This beta-1 selective adrenergic receptor antagonist represents a well-established compound class extensively studied in cardiovascular pharmacology research. The extended-release formulation provides sustained compound availability for prolonged experimental protocols, making it valuable for researchers investigating beta-blocker mechanisms and cardiovascular pathophysiology models.
Metoprolol tartrate demonstrates selective antagonism at beta-1 adrenergic receptors with minimal intrinsic sympathomimetic activity. Research applications span from basic receptor pharmacology studies to complex cardiovascular disease models. The compound’s selectivity profile and pharmacokinetic properties have made it a reference standard in beta-blocker research since its initial development. Scientists examining hypertension models, cardiac arrhythmia mechanisms, and myocardial protection pathways frequently incorporate this compound into their experimental designs.
Our research facility at Stroid UK Shop maintains comprehensive quality standards for all pharmaceutical compounds. Researchers investigating cardiovascular drugs can access detailed certificates of analysis with each order. While our primary focus remains SARMs and peptides, our cardiovascular research compounds meet equivalent analytical standards.
Laboratory Research Applications
Cardiovascular research laboratories utilise metoprolol formulations to investigate beta-adrenergic signalling pathways, cardiac electrophysiology, and vascular smooth muscle responses. The compound’s established pharmacological profile enables researchers to examine dose-response relationships, receptor selectivity mechanisms, and therapeutic index parameters in controlled experimental settings. Studies examining cardiac output regulation, coronary blood flow dynamics, and myocardial oxygen consumption frequently incorporate metoprolol as either a primary research compound or comparative control.
Extended-release formulations like Topme-XL provide sustained compound exposure suitable for chronic treatment protocols and long-term cardiovascular adaptation studies. Researchers studying cardiac remodelling, exercise physiology, and cardiovascular disease progression benefit from the consistent compound levels achieved with controlled-release systems. The formulation’s pharmaceutical engineering allows investigation of sustained beta-blockade effects without frequent dosing interventions.
Pharmaceutical Specifications
| Parameter | Specification |
|---|---|
| Active Compound | Metoprolol Tartrate |
| Strength | 50 mg per tablet |
| Manufacturer | Johnlee Pharmaceuticals |
| Formulation | Extended-Release Tablet |
| CAS Number | 56392-17-7 (Metoprolol Tartrate) |
| Storage Conditions | Room temperature, dry environment |
Research Compliance Notice
Topme-XL 50 mg is supplied exclusively for in-vitro laboratory research and analytical purposes. This pharmaceutical compound is not intended for human consumption, therapeutic use, or any clinical applications. Researchers must ensure appropriate laboratory safety protocols and regulatory compliance when handling this material. All studies should be conducted within approved research facilities with proper institutional oversight and ethical approval where applicable.
